Intranasal Apomorphine Rescue Therapy for Parkinsonian "Off" Periods

Clinical Neuropharmacology

Volumn 19, Issue 3, 1996, Pages 193-201

  Dewey Jr , Richard B ^a,c   Maraganore, Demetrius M ^b   Ahlskog, J Eric ^b   Matsumoto, Joseph Y ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Apomorphine; Dopamine agonists; Motor fluctuations; Parkinson's disease; Rescue therapy; Trimethobenzamide

Indexed keywords

APOMORPHINE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; TRIMETHOBENZAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSKINESIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NAUSEA; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANTIEMETICS; ANTIPARKINSON AGENTS; APOMORPHINE; BENZAMIDES; CARBIDOPA; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; LEVODOPA; MALE; MIDDLE AGED; NAUSEA; PARKINSON DISEASE; VOMITING;

EID: 0029968679     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619030-00001     Document Type: Article

References (12)

1. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986;36:1528-30.
2. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
3. Van Laar T, Jansen EN, Essink AW, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol 1992;49:482-4.
4. Kleedorfer B, Turjanski N, Ryan R, Lees AJ, Milroy C, Stern GM. Intranasal apomorphine in Parkinson's disease. Neurology 1991;41:761-2.
5. Kapoor R, Turjanski N, Frankel J, et al. Intranasal apomorphine: a new treatment in Parkinson's disease [Letter]. J Neurol Neurosurg Psychiatry 1990;53:1015.
6. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat 1968;5:257-82.
7. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurological deficit. Boston: Butterworths, 1989:285-309.
8. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993;7:121-8.
9. Elliot PNC, Jenner P, Huizing G, Marsden CD, Miller R. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology 1977;16:333-42.
10. Corsini GU, Del Zompo M, Cianchetti C, Mangoni A. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacology 1976;47: 169-73.
11. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-6.
12. Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A. Naloxone partly counteracts apomorphine side effects. Clin Neuropharmacol 1991;14:442-9.